Viking Therapeutics (SYM: VKTX) may be one of the hottest biotech stocks to buy this year.
Now trading at $65.52, we strongly believe VKTX could run back to all-time highs, as it nears Phase 3 trials for its obesity treatment, VK2735.
The company just announced plans to start a late-stage trial for its obesity drug VK2735 later this year. “We are advancing this compound into Phase 3 development,” CEO Brian Lian said, as noted in a company press release, adding that “we are currently preparing for an end-of-phase 2 meeting with the agency, which we expect to occur later this year.”
In addition, Phase 1 trials of the oral form of the treatment showed encouraging safety and tolerability, with positive signs of clinical activity, as noted in a company press release. Patients also reported a mean weight loss of up to 5.3% from baseline after 28 days. The company expects to move into Phase 2 with the oral treatment later this year.
